Researchers at Hangzhou Glubio Therapeutics Co. Ltd. have patented isoindolinone molecular glue degraders that induce DNA-binding protein Ikaros (IKZF1) degradation and are reported to be useful for the treatment of cancer.
A Katholieke Universiteit Leuven patent details 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues that act as viral replication inhibitors potentially useful for the treatment of viral infections.
Research at Medshine Discovery Inc. has led to the development of imidazocyclic compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of diabetes.
Redx Pharma plc has described henyl- and pyridopyrazole derivatives as discoidin domain-containing receptor DDR1 and/or DDR2 inhibitors. They are reported to be useful for the treatment of fibrosis, cancer, transplant rejection, inflammatory, renal, liver and cardiovascular disorders.
Suzhou Genhouse Bio Co. Ltd. has prepared and tested new histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, asthma, Alzheimer’s diseases, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.
Research at Middle Tennessee State University has led to the development of peptoids reported to be useful for the treatment of fungal infections and tuberculosis.
A recent Nurix Therapeutics Inc. patent describes proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker reported to be useful for the treatment of cancer, metabolic diseases and inflammatory disorders.
Pardes Biosciences Inc. has patented 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections.
RSS